Cebranopadol: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store at controlled room temperature (20-25 degrees C). Protect from light and moisture. Specific storage conditions may vary by formulation.
Protocol Quick-Reference
Moderate-to-severe acute and chronic pain
Dosing
Amount
400 mcg once daily (acute); 200-600 mcg once daily (chronic)
Frequency
Once daily
Duration
2 days (acute); ongoing (chronic)
Step-wise Titration (4 weeks)
Administration
Route
OralSchedule
Once daily
Timing
Once-daily dosing supported by long half-life (62-96 hours terminal)
Cycle
Duration
As prescribed
Repeatable
Yes
Preparation & Storage
โ Ready-to-use โ no reconstitution required
Storage: Room temperature (20-25 degrees C). Protect from light and moisture.
๐ก Key Considerations
- โInvestigational drug - not yet approved by any regulatory authority
- โTitration recommended for chronic pain to minimize adverse events during initiation
- โLong terminal half-life means steady state reached in approximately 2 weeks
- โOnce-daily dosing regardless of indication
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Acute Pain (Phase 3 Protocol) | 400 mcg orally once daily for up to 2 days. Administered as a single oral dose per day. | Once daily oral administration | 2 days (acute pain setting) | Protocol used in ALLEVIATE-1 (abdominoplasty) and ALLEVIATE-2 (bunionectomy) Phase 3 trials. No titration required for acute use. |
| Chronic Low Back Pain (Phase 2 Protocol) | 200, 400, or 600 mcg orally once daily. Dose titration during initial weeks to target dose, followed by maintenance period. | Once daily oral administration | 14 weeks (titration + maintenance) | Higher doses (600 mcg) associated with more adverse events during titration. Patients reaching target doses had acceptable tolerability. Adverse event incidence during maintenance was 10% or less for individual events. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Cebranopadol is formulated as an oral tablet or capsule. No reconstitution is required. The compound is a small molecule (not a peptide requiring reconstitution) administered orally.
๐งStorage Requirements
Store at controlled room temperature (20-25 degrees C). Protect from light and moisture. Specific storage conditions may vary by formulation.
Community Dosing Protocols
Compare these clinical doses with what 10+ community members report using.
Based on 10+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
Cebranopadol (GRT-6005) is an investigational medication that has not received regulatory approval. All dosing information is derived from clinical trial protocols and published study results. This information is provided for research reference only.
Clinical Trial Dosing#
Acute Pain (Phase 3 Protocol)#
In the pivotal ALLEVIATE-1 and ALLEVIATE-2 Phase 3 trials, cebranopadol was dosed as follows:
- Dose: 400 mcg orally once daily
- Duration: 2 days of treatment
- Timing: First dose administered following surgery once pain was moderate to severe
- No titration: Fixed dose without titration for short-term acute use
Both trials demonstrated significant pain reduction compared to placebo (p<0.001 in each), and in ALLEVIATE-2, cebranopadol showed comparable or superior efficacy to oxycodone IR 10 mg four times daily.
Chronic Low Back Pain (Phase 2 Protocol)#
The Phase 2 chronic LBP trial used a titration-to-maintenance approach:
Titration Phase:
- Starting dose: 200 mcg once daily
- Gradual uptitration to target dose
- Target doses studied: 200, 400, or 600 mcg once daily
Maintenance Phase (up to 14 weeks total):
- Fixed dose at the assigned target level
- Individual adverse event rates during maintenance were 10% or less
Phase 2a Postoperative Pain#
Single-dose protocol in bunionectomy patients:
- Cebranopadol 200, 400, or 600 mcg as a single oral dose
- Analgesic effect of 400-600 mcg doses lasted approximately 22 hours
- 400 mcg was better tolerated than morphine CR 60 mg
Pharmacokinetic Considerations#
Cebranopadol has distinctive pharmacokinetic properties that inform dosing:
| Parameter | Value |
|---|---|
| Time to peak concentration (Tmax) | 4-6 hours |
| Half-value duration (HVD) | 14-15 hours |
| Terminal half-life | 62-96 hours |
| Operational half-life (steady state) | ~24 hours |
| Time to steady state | ~2 weeks |
| Accumulation factor | ~2 |
| Peak-trough fluctuation | 70-80% (low) |
The long terminal half-life and low peak-trough fluctuation support once-daily dosing with relatively stable plasma concentrations at steady state.
Dose-Response Considerations#
- Acute pain: 400 mcg once daily has been the consistent dose across both Phase 3 trials, providing optimal balance of efficacy and tolerability
- Chronic pain: 200, 400, and 600 mcg all showed efficacy, but higher doses were associated with more adverse events during titration
- Abuse potential: At clinical doses (200-400 mcg), cebranopadol did not differ from placebo on drug-liking assessments; 800 mcg showed some abuse signal
Route of Administration#
Cebranopadol is administered orally and does not require injection, reconstitution, or any specialized preparation. This differentiates it from many other pain-related peptide therapies (such as ziconotide, which requires intrathecal administration).
Storage#
Store at controlled room temperature (20-25 degrees C). Protect from light and moisture. Specific storage requirements will be determined by the final commercial formulation.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Cebranopadol
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.